Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00529581 · ClinicalTrials.gov registry record · Phase 2
A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis
A Phase 2 study of Multiple Sclerosis and Cognition Disorders, sponsored by Cognition Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT00529581 is a Phase 2 study of Multiple Sclerosis and Cognition Disorders that has completed, run by Cognition Pharmaceuticals. The registered enrollment target is 150 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT00529581, a Phase 2 study of Multiple Sclerosis and Cognition Disorders, has completed, sponsored by Cognition Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety and efficacy of C105 in treating the cognitive deficits that can occur due to multiple sclerosis.
Conditions Studied
Interventions
- DRUG C105
Study Locations (20)
Florida
- Neurology Associates, PA - Maitland
- Lovelace Scientific Resources - Sarasota
- Roskamp Institute - Sarasota
- Suncoast Neuroscience Associates, Inc. - St. Petersburg
- Axiom Clinical Research of Florida - Tampa
Connecticut
- Associated Neurologists, P.C. - Danbury
- Associated Neurologist of Southern Connecticut, PC - Fairfield
- Yale University MS Center - New Haven
Arizona
- Saint Joseph's Hospital, Barrow Neurology Clinics - Phoenix
- Northwest Neuro Specialists, PLLC - Tuscon
California
- Research Center for Clinical Studies West - Lancaster
- Loma Linda University, Department of Neurology - Loma Linda
Kansas
- University of Kansas Medical Center, Department of Neurology - Kansas City
- MidAmerica Neuroscience Institute - Lenexa
Michigan
- Henry Ford Health System, Department of Neurology - Detroit
- Northern Michigan Neurology - Traverse City
Georgia
- Shepard Center - Atlanta
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00529581
The ClinicalTrials.gov registry entry for NCT00529581 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (74% lower). The listed sponsor is Cognition Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which C105 is the first listed.
NCT00529581 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Connecticut, Arizona.
Frequently Asked Questions
What is clinical trial NCT00529581 about?
NCT00529581 is a clinical study titled "A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis". The purpose of this study is to determine the safety and efficacy of C105 in treating the cognitive deficits that can occur due to multiple sclerosis.
What is the current status of trial NCT00529581?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2006-11. Estimated completion is 2008-04.
What conditions does trial NCT00529581 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Cognition Disorders.
What interventions are being tested in trial NCT00529581?
The interventions under investigation include: C105 (DRUG).
Who is sponsoring clinical trial NCT00529581?
This trial is sponsored by Cognition Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00529581 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
RECRUITING · Phase 2
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.